ClinicalTrials.gg
CompletedNCT00313794Updated Jun 7, 2012

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

A Phase 2 interventional study of CP-675,206 in Colorectal Neoplasms, sponsored by AstraZeneca. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-07.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing tremelimumab in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. tremelimumab · Colorectal Neoplasms.

Enrollment
5th of 14
49 · median 34
Started
2006
the only one that year
Phase 2
8 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
2 of 14
AstraZeneca

Among the 14 studies testing tremelimumab in Colorectal Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2006, is one of 8 in phase 2, and was the 1st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies testing tremelimumab in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tremelimumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. Patients who are intolerant to treatment(s) are also included. This is a study for good performance status colorectal cancer patients who have exhausted standard therapy options.

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radiographic evidence of , progressive disease following standard therapies.
  • (ECOG) performance status 0-1.

Exclusion criteria

Exclusion Criteria:

  • Known or uncontrolled pleural effusions.
  • History of chronic inflammatory or disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    1

    single arm

    Drug: CP-675,206

Interventions

  • 15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.

    Also known as: ticilimumab, tremelimumab

06

What researchers measure

Primary outcomes

  1. To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with CP-675,206 .

    Time frame: 18 months

Secondary outcomes

  1. To evaluate the safety and tolerability of CP-675,206 in this population.

    Time frame: 18 mos

  2. To identify any human anti human antibody (HAHA) response to CP-675,206 .

    Time frame: 3 yrs

  3. To identify potential relationships between polymorphisms in the Cytotoxic T lymphocyte-associated antigen 4 (CTLA4), Fcgamma receptor IIa (FcgRIIa), IgG2a genes with safety and/or immune response of patients treated with CP-675,206.

    Time frame: 3 yrs

  4. To assess additional evidence of anti-tumor activity as measured by duration of response, progression-free survival and overall survival.

    Time frame: 2 yrs

  5. To obtain pharmacokinetic (PK) data to be evaluated in a future meta analysis of CP-675,206 pharmacokinetics.

    Time frame: 3 yrs

07

Study locations

11 sites
  • Research Site
    Bessemer, Alabama 35022, United States
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Birmingham, Alabama 35211, United States
  • Research Site
    Birmingham, Alabama 35213, United States
  • Research Site
    Birmingham, Alabama 35235, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    New York, New York 10022, United States
  • Research Site
    Levis, Quebec G6V 3Z1, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2006
First posted
Apr 12, 2006
Start
May 2006
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results delay requested
Mar 20, 2009
Last update
Jun 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00313794
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 12, 2006
Start date
May 2006
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Jun 7, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion